24 |
Approval of IND for phase I clinical trial for Endolysin LNT103 |
LyseNTech |
2024-04-03 |
55 |
23 |
LyseNTech selected for the GloPID-R project |
LyseNTech |
2024-04-03 |
39 |
22 |
LyseNTech filed IND for phase 1 clinical trial of its endolysin |
LyseNTech |
2023-11-23 |
212 |
21 |
LyseNTech acquired US patent for endolysin LNT103 |
LyseNTech |
2023-11-22 |
173 |
20 |
LyseNTech won the grand prize at the 2023 Gyeonggi Startup Investment Conference & Global Day |
LyseNTech |
2023-11-03 |
242 |
19 |
Heejoon Myung, CEO of LyseNTech, presented at the 2023 Korean Society of Infectious Diseases |
LyseNTech |
2023-11-03 |
226 |
18 |
Poster presentation in World AMR Congress 2023 (Philadelphia, USA) |
LyseNTech |
2023-09-21 |
258 |
17 |
Oral presentation in The 1st International Symposium for Infectious Diseases Research Institutes Cooperation |
LyseNTech |
2023-09-21 |
255 |
16 |
Oral presentation in 26th Congress of the Asian Pacific Society of Respirology |
LyseNTech |
2023-09-21 |
264 |
15 |
Participation in Phage Australia |
LyseNTech |
2023-09-21 |
246 |